Indeed, although some groups have shown correlations between in vitro lytic function of CAR-T products with in vivo efficacy in animal models (5), studies of CAR-T cell trials have shown that cytokine release and in vitro tumour lysis assays do not predict clinical efficacy (6), even for CD19-CAR-T targeting haematologic disease. Here, CD19 is linked to neoplasm.